查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1466564

抗体片段市场：按类型、抗体类型、应用划分 - 2024-2030 年全球预测

Antibody Fragments Market by Type (F(ab) Fragments, F(ab')2 Fragments, Single Domain Antibody Fragments (sdAbs)), Antibody Type (Monoclonal, Polyclonal), Application - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计2023年抗体片段市场规模为77.2亿美元，预计2024年将达到80.7亿美元，2030年将达到104.2亿美元，复合年增长率为4.36%。

抗体片段是抗体的一部分，可以与特定类型的抗原结合，抗原是体内引起免疫反应的外来物质。抗体片段通常衍生完整抗体，并透过酵素消化或基因工程技术开发。这个市场开拓的关键驱动力是越来越多地采用标靶治疗来治疗自体免疫疾病等慢性疾病。遗传和生化技术的进步也为增强这些片段的生产和工程化铺平了道路，从而推动了成长。研发资金的不断增加和强大的医疗基础设施（尤其是在已开发国家）促进了整体市场的成长。然而，生产和精製抗体片段的高成本可能会限制市场成长。新兴市场的监管挑战和缺乏认识也是潜在的成长阻碍因素。新的可能性包括使用抗体片段开发创新药物并将其用于开拓的疾病领域。此外，新兴市场製药和生物技术工作的扩展和整合也为抗体片段市场的成长带来了重大机会。

主要市场统计
基准年[2023] 77.2亿美元
预测年份 [2024] 80.7亿美元
预测年份 [2030] 104.2亿美元
复合年增长率（%） 4.36%

单域抗体 (sdAb) 由于其稳定性和灵活的结合而在应用中迅速普及。

F(ab) 片段是具有单一抗原结合位点 (Fab) 的小抗体片段。由于它没有保守的 Fc 区，因此不能透过抗体依赖性细胞毒性来破坏细胞。应用于影像诊断、诊断药物等。与 F(ab) 相比，F(ab')2 片段具有两个抗原结合位点，使抗体能够更牢固地与其标靶结合。与 F(ab)2 片段相比，F(ab')2 片段具有两个抗原结合位点，可以更强地结合标靶。单域抗体 (sdAb) 以其高溶解度、热稳定性和与酶活性位点结合的能力而闻名，在治疗和研究中具有广泛的用途。单链可变片段 (scFv) 具有与单株抗体类似的结合特异性。作为设计抗体衍生物的有效工具，它受到标靶药物递送和免疫治疗的青睐。

抗体类型：单株抗体的使用由于其在标靶治疗中的高特异性而不断增加。

单株抗体 (MAb) 是由单一 B 细胞克隆产生的相同抗体。单株抗体对单一抗原决定簇具有特异性，具有高特异性、一致的品质和无限的供应。例子包括特定蛋白质的检测和定量、肿瘤和自体免疫疾病等治疗领域，以及细胞和组织的染色，在这些领域中，仅检测感兴趣的抗原很重要。多株抗体(PAb) 是体内不同 B 细胞克隆产生的抗体混合物，每种抗体识别抗原上的不同表位。其结果是产生一系列在某些条件下可能有益的反应。多株抗体是需要在检测系统中提供强大讯号的研究的首选，例如蛋白质印迹、ELISA 和免疫组织化学。由于 PAb 在不同条件下可以结合多个表位，因此能够耐受抗原构象的微小变化。可以提供比单株抗体更高的整体结合亲和性。

应用 抗体片段在癌症治疗的应用进展

抗体片段在癌症治疗的应用被认为是癌症研究的突破。它们的小尺寸使它们能够比完整抗体更有效地穿透并结合癌细胞。此外，它可以最大限度地减少对健康细胞造成附带损害的风险，并提供更有针对性的治疗方法。抗体片段在免疫力缺乏的治疗中极为重要。抗体片段补偿缺失或不足的抗体反应，并提高患者抵抗感染疾病的能力。它们还可以针对特定疾病生物标记进行设计，从而实现更个性化的治疗。虽然癌症治疗主要着重于针对性地清除癌细胞，免疫力缺乏使用抗体片段来增强人体的免疫反应。

区域洞察

由于持续的研究倡议为市场成长铺平了道路，美洲在抗体片段市场中占有重要地位。这些国家的购买行为很大程度上是由个人化医疗的出现所推动的，特别关注特异性疾病的应用。随着私人和政府对下一代医疗保健技术的投资增加，预计将进一步成长。由于健康意识的提高和政府的公共卫生倡议，欧洲、中东和非洲 (EMEA) 是一个快速增长的抗体片段市场。这些地区与文明病呈上升趋势，医疗保健领域需要创新的治疗方法。欧盟国家和中东地区正在对诊断技术和研究进行大量投资，提供了广泛的市场潜力。亚太地区是一个新兴的医疗保健影响者和对抗体片段的需求不断增长的地区。该领域不断增加的研发投资显示该地区市场成长前景广阔。该地区的客户行为揭示了对治疗应用的倾向，许多製造商希望利用这一点，进一步推动该地区的市场成长。

FPNV定位矩阵

FPNV定位矩阵对于评估抗体片段市场至关重要。我们检视与业务策略和产品满意度相关的关键指标，以对供应商进行全面评估。这种深入的分析使用户能够根据自己的要求做出明智的决策。根据评估，供应商被分为四个成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市场占有率分析

市场占有率分析是一种综合工具，可以对抗体片段市场供应商的现状进行深入而深入的研究。全面比较和分析供应商在整体收益、基本客群和其他关键指标方面的贡献，以便更好地了解公司的绩效及其在争夺市场占有率时面临的挑战。此外，该分析还提供了对该行业竞争特征的宝贵见解，包括在研究基准年观察到的累积、分散主导地位和合併特征等因素。详细程度的提高使供应商能够做出更明智的决策并制定有效的策略，从而在市场上获得竞争优势。

本报告在以下方面提供了宝贵的见解：

1. 市场渗透率：提供有关主要企业所服务的市场的全面资讯。

2. 市场开拓：我们深入研究利润丰厚的新兴市场，并分析其在成熟细分市场的渗透率。

3. 市场多元化：提供有关新产品发布、开拓地区、最新发展和投资的详细资讯。

4.竞争力评估与资讯：对主要企业的市场占有率、策略、产品、认证、监管状况、专利状况、製造能力等进行全面评估。

5. 产品开发与创新：提供对未来技术、研发活动和突破性产品开发的见解。

本报告解决了以下关键问题：

1. 抗体片段市场的市场规模与预测是多少？

2.抗体片段市场预测期内需要考虑投资的产品、细分市场、应用和领域有哪些？

3.抗体片段市场的技术趋势和法规结构是什么？

4.抗体片段市场主要厂商的市场占有率为何？

5. 进入抗体片段市场的合适型态和策略手段是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 抗体片段在医学诊断的使用增加
      • 各种癌症和感染疾病的发生率增加
      • 药物发现活动的增加
    • 抑制因素
      • 抗体片段核准的严格监管指南
    • 机会
      • 抗体片段临床开发进展
      • 先进重组DNA技术简介
    • 任务
      • 抗癌免疫疗法疗效不足且副作用大
  • 市场区隔分析
    • 类型：由于结合稳定性和弹性，从应用角度来看，单域抗体片段（sdAb）的使用正在迅速增加
    • 抗体类型：标靶治疗的高特异性扩大了单株抗体的用途
    • 应用：抗体片段在癌症治疗中应用的演变
  • 市场扰动分析
  • 波特五力分析
  • 价值炼和关键路径分析
  • 价格分析
  • 技术分析
  • 专利分析
  • 贸易分析
  • 法规结构分析

第六章抗体片段市场：依类型

  • F(ab) 片段
  • F(ab')2 片段
  • 单域抗体片段 (sdAb)
  • 单链可变片段（scFv）

第七章抗体片段市场：按抗体类型

  • 单复製
  • 多克隆抗体

第八章抗体片段市场：依应用分类

  • 癌症
  • 免疫力缺乏

第九章美洲抗体片段市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太抗体片段市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章 欧洲、中东和非洲抗体片段市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • Lupin 和 Amman Pharma 合作独家经销雷珠单抗
    • 伯明罕血小板集团推出突破性「奈米抗体」技术
    • Atovia 是一家加州新创生技公司，成立的目的是重新思考药物如何与目标结合。
  • 战略分析和建议

第13章竞争产品组合

  • 主要企业简介
  • 主要产品系列
Product Code: MRR-F927BA461FE0

[189 Pages Report] The Antibody Fragments Market size was estimated at USD 7.72 billion in 2023 and expected to reach USD 8.07 billion in 2024, at a CAGR 4.36% to reach USD 10.42 billion by 2030.

Antibody fragments refer to parts of antibodies capable of binding to specific types of antigens, the foreign substances in the body that induce an immune response. Antibody fragments are usually derivatives from whole antibodies and are developed through enzyme digestion or genetic engineering techniques. The primary driver of this market development is the increasing adoption of targeted therapies for treating chronic conditions, such as autoimmune diseases. Advancements in genetic and biochemical technologies have also paved the way for enhanced production and engineering of these fragments, boosting growth. A constant increase in R&D funding and robust healthcare infrastructure, especially in developed countries, contributed to overall market growth. However, the high costs of producing and purifying antibody fragments can restrict market growth. Regulatory challenges and lack of awareness in emerging markets also pose potential growth restrictions. New avenues for potential opportunities include the development of innovative drugs using antibody fragments and their usage in untapped disease areas. Additionally, the expansion and consolidation of pharmaceutical and biotechnological efforts in emerging markets also present significant opportunities for growth in the antibody fragments market.

KEY MARKET STATISTICS
Base Year [2023] USD 7.72 billion
Estimated Year [2024] USD 8.07 billion
Forecast Year [2030] USD 10.42 billion
CAGR (%) 4.36%

Type: Burgeoning usage of single domain antibody fragments (sdAbs) in terms of applications due to their stability and flexibility in binding

F(ab) Fragments are small antibody fragments that contain one antigen-binding (Fab) site. It does not present the conserved Fc region; therefore, it cannot destroy cells through antibody-dependent cellular cytotoxicity. Applications include imaging and diagnostics. F(ab')2 Fragments, compared to F(ab), contain two antigen-combining sites, enabling the antibody to bind more vigorously to its targets. It is appreciated for allowing a more concentrated tracking accuracy in in-vivo imaging. Single domain antibody fragments (sdAbs) are known for their high solubility, thermal stability, and ability to bind to enzyme active sites, making their uses variegated in therapeutics and undergoing research. Single-chain variable fragments (scFvs) have binding specificity similar to monoclonal antibodies. They are preferred for targeted drug delivery and immunotherapy as efficient tools for the design of antibody derivatives.

Antibody Type: Proliferating utilization of monoclonal antibodies owing to their high specificity in targeted therapeutics

Monoclonal antibodies(MAbs) are identical antibodies made by a single B-cell clone. They are specific for a single antigenic determinant, resulting in high specificity, consistently high quality, and unlimited supply. On a needs-based perspective, monoclonal antibodies are preferred in situations necessitating a high degree of specificity, such as in assays for detection and quantification of specific proteins, therapeutic areas such as oncology, autoimmune disorders, and in cell and tissue staining where it's critical to detect only the antigen of interest. Polyclonal antibodies (PAbs) are a mix of antibodies produced by different B cell clones in the body, each recognizing a different epitope of an antigen. This results in a broad-spectrum response that can be beneficial under certain conditions. Polyclonal antibodies are preferred in research requiring robust signals in detection systems such as Western blot, ELISA, or immunohistochemistry. Their capacity to bind multiple epitopes under varying conditions makes the PAbs more forgiving to slight changes in antigen conformation. It can offer a higher overall binding affinity than monoclonal antibodies.

Application: Evolving application of antibody fragments in cancer therapy

Antibody fragments in cancer therapy have been regarded as a breakthrough in oncology research. Their small size makes them penetrate and bind to cancer cells more efficiently than whole antibodies. Moreover, they minimize the risk of collateral damage to healthy cells, offering a more targeted treatment approach. Antibody fragments have been crucial in the treatment of immunodeficiencies. They help replace missing or inadequate antibody responses, improving the patient's ability to fight off infections. They offer more personalized treatment owing to their ability to be engineered to target specific disease biomarkers. Cancer treatment mainly focuses on the targeted elimination of cancer cells, whereas, in immunodeficiencies, antibody fragments are employed to boost the body's immune response.

Regional Insights

The Americas has a significant landscape in the antibody fragments market owing to ongoing research initiatives that pave the way for the market's growth. The purchasing behavior in these countries is predominantly driven by the advent of personalized medicine, with a notable focus on disease-specific applications. With the rising private and government entities' investments in next-generation healthcare technologies, further growth is anticipated. Europe, the Middle East, and Africa (EMEA) exhibit a burgeoning market for antibody fragments, driven by a rise in health consciousness and governmental initiatives for public health. The increase in lifestyle diseases in these regions has necessitated innovative therapeutics in the healthcare sector. EU countries and the Middle East are experiencing heavy investments in diagnostic technologies and research, thus promising market potential. The Asia Pacific region, home to emerging healthcare influencers, is witnessing a growing demand for antibody fragments. Increased investments in research & development in the field indicate a promising market growth in this region. The customer behavior in this region reveals an inclination towards therapeutic applications, which many manufacturers are looking to capitalize on, further increasing the market growth in the area.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Antibody Fragments Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Antibody Fragments Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Antibody Fragments Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Adaptimmune Therapeutics PLC, Aenova Group GmbH, Almac Group, Amgen Inc., Antikor Biopharma, Astellas Pharma Inc., Baxter International Inc., Biogen Inc., Bristol-Myers Squibb Company, Confo Therapeutics, Dyne Therapeutics, Eli Lilly and Company, Evonik Industries AG, F. Hoffmann-La Roche Ltd., Genentech, Inc., Gilde Healthcare, Johnson & Johnson Services, Inc., MoonLake Immunotherapeutics AG, Novartis AG, Numab AG, Pfizer Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Antibody Fragments Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Type
    • F(ab) Fragments
    • F(ab')2 Fragments
    • Single Domain Antibody Fragments (sdAbs)
    • Single-chain Variable Fragments (scFvs)
  • Antibody Type
    • Monoclonal
    • Polyclonal
  • Application
    • Cancer
    • Immunodeficiencies
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Antibody Fragments Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Antibody Fragments Market?

3. What are the technology trends and regulatory frameworks in the Antibody Fragments Market?

4. What is the market share of the leading vendors in the Antibody Fragments Market?

5. Which modes and strategic moves are suitable for entering the Antibody Fragments Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing use of antibody fragments in medical diagnostics
      • 5.1.1.2. Rising incidences of various cancers and infectious diseases
      • 5.1.1.3. Increasing number of drug discovery activities
    • 5.1.2. Restraints
      • 5.1.2.1. Strict regulatory guidelines for the approval of antibody fragments
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements in the clinical development of antibody fragments
      • 5.1.3.2. Introduction of advanced recombinant DNA technology
    • 5.1.4. Challenges
      • 5.1.4.1. Insufficient efficacy and adverse effects in anticancer immunotherapy
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Burgeoning usage of single domain antibody fragments (sdAbs) in terms of applications due to their stability and flexibility in binding
    • 5.2.2. Antibody Type: Proliferating utilization of monoclonal antibodies owing to their high specificity in targeted therapeutics
    • 5.2.3. Application: Evolving application of antibody fragments in cancer therapy
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. Antibody Fragments Market, by Type

  • 6.1. Introduction
  • 6.2. F(ab) Fragments
  • 6.3. F(ab')2 Fragments
  • 6.4. Single Domain Antibody Fragments (sdAbs)
  • 6.5. Single-chain Variable Fragments (scFvs)

7. Antibody Fragments Market, by Antibody Type

  • 7.1. Introduction
  • 7.2. Monoclonal
  • 7.3. Polyclonal

8. Antibody Fragments Market, by Application

  • 8.1. Introduction
  • 8.2. Cancer
  • 8.3. Immunodeficiencies

9. Americas Antibody Fragments Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Antibody Fragments Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Antibody Fragments Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Lupin, Amman Pharma Collaborates for Exclusive Marketing of Ranibizumab
    • 12.3.2. Birmingham Platelet Group Delivers Breakthrough 'nanobody' Technology
    • 12.3.3. Attovia, a new California biotech, Launches with Plans to Rethink how Drugs Bind their Targets
  • 12.4. Strategy Analysis & Recommendation

13. Competitive Portfolio

  • 13.1. Key Company Profiles
  • 13.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. ANTIBODY FRAGMENTS MARKET RESEARCH PROCESS
  • FIGURE 2. ANTIBODY FRAGMENTS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. ANTIBODY FRAGMENTS MARKET DYNAMICS
  • FIGURE 7. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS ANTIBODY FRAGMENTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 14. AMERICAS ANTIBODY FRAGMENTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES ANTIBODY FRAGMENTS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 16. UNITED STATES ANTIBODY FRAGMENTS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. ASIA-PACIFIC ANTIBODY FRAGMENTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. ASIA-PACIFIC ANTIBODY FRAGMENTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ANTIBODY FRAGMENTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ANTIBODY FRAGMENTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. ANTIBODY FRAGMENTS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 22. ANTIBODY FRAGMENTS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ANTIBODY FRAGMENTS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY F(AB) FRAGMENTS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY F(AB) FRAGMENTS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY F(AB')2 FRAGMENTS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY F(AB')2 FRAGMENTS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY SINGLE DOMAIN ANTIBODY FRAGMENTS (SDABS), BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY SINGLE DOMAIN ANTIBODY FRAGMENTS (SDABS), BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY SINGLE-CHAIN VARIABLE FRAGMENTS (SCFVS), BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY SINGLE-CHAIN VARIABLE FRAGMENTS (SCFVS), BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY MONOCLONAL, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY MONOCLONAL, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY POLYCLONAL, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY POLYCLONAL, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY IMMUNODEFICIENCIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY IMMUNODEFICIENCIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. AMERICAS ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 30. AMERICAS ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 31. AMERICAS ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
  • TABLE 32. AMERICAS ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
  • TABLE 33. AMERICAS ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 34. AMERICAS ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 35. AMERICAS ANTIBODY FRAGMENTS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 36. AMERICAS ANTIBODY FRAGMENTS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 37. ARGENTINA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 38. ARGENTINA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 39. ARGENTINA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
  • TABLE 40. ARGENTINA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
  • TABLE 41. ARGENTINA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 42. ARGENTINA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 43. BRAZIL ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 44. BRAZIL ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 45. BRAZIL ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
  • TABLE 46. BRAZIL ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
  • TABLE 47. BRAZIL ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 48. BRAZIL ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 49. CANADA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 50. CANADA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 51. CANADA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
  • TABLE 52. CANADA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
  • TABLE 53. CANADA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 54. CANADA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 55. MEXICO ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 56. MEXICO ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 57. MEXICO ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
  • TABLE 58. MEXICO ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
  • TABLE 59. MEXICO ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 60. MEXICO ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 61. UNITED STATES ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 62. UNITED STATES ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 63. UNITED STATES ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
  • TABLE 64. UNITED STATES ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
  • TABLE 65. UNITED STATES ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 66. UNITED STATES ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 67. UNITED STATES ANTIBODY FRAGMENTS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 68. UNITED STATES ANTIBODY FRAGMENTS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 69. ASIA-PACIFIC ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 70. ASIA-PACIFIC ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 71. ASIA-PACIFIC ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
  • TABLE 72. ASIA-PACIFIC ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
  • TABLE 73. ASIA-PACIFIC ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 74. ASIA-PACIFIC ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC ANTIBODY FRAGMENTS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC ANTIBODY FRAGMENTS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 77. AUSTRALIA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 78. AUSTRALIA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 79. AUSTRALIA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
  • TABLE 80. AUSTRALIA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
  • TABLE 81. AUSTRALIA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 82. AUSTRALIA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 83. CHINA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 84. CHINA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 85. CHINA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
  • TABLE 86. CHINA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
  • TABLE 87. CHINA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 88. CHINA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 89. INDIA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 90. INDIA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 91. INDIA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
  • TABLE 92. INDIA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
  • TABLE 93. INDIA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 94. INDIA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 95. INDONESIA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 96. INDONESIA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 97. INDONESIA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
  • TABLE 98. INDONESIA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
  • TABLE 99. INDONESIA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 100. INDONESIA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 101. JAPAN ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 102. JAPAN ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 103. JAPAN ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
  • TABLE 104. JAPAN ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
  • TABLE 105. JAPAN ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 106. JAPAN ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 107. MALAYSIA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 108. MALAYSIA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 109. MALAYSIA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
  • TABLE 110. MALAYSIA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
  • TABLE 111. MALAYSIA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 112. MALAYSIA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 113. PHILIPPINES ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 114. PHILIPPINES ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 115. PHILIPPINES ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
  • TABLE 116. PHILIPPINES ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
  • TABLE 117. PHILIPPINES ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 118. PHILIPPINES ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 119. SINGAPORE ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 120. SINGAPORE ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 121. SINGAPORE ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
  • TABLE 122. SINGAPORE ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
  • TABLE 123. SINGAPORE ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 124. SINGAPORE ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 125. SOUTH KOREA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 126. SOUTH KOREA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 127. SOUTH KOREA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
  • TABLE 128. SOUTH KOREA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
  • TABLE 129. SOUTH KOREA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 130. SOUTH KOREA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 131. TAIWAN ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 132. TAIWAN ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 133. TAIWAN ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
  • TABLE 134. TAIWAN ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
  • TABLE 135. TAIWAN ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 136. TAIWAN ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 137. THAILAND ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 138. THAILAND ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 139. THAILAND ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
  • TABLE 140. THAILAND ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
  • TABLE 141. THAILAND ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 142. THAILAND ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 143. VIETNAM ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 144. VIETNAM ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 145. VIETNAM ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
  • TABLE 146. VIETNAM ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
  • TABLE 147. VIETNAM ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 148. VIETNAM ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA ANTIBODY FRAGMENTS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA ANTIBODY FRAGMENTS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 157. DENMARK ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 158. DENMARK ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 159. DENMARK ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
  • TABLE 160. DENMARK ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
  • TABLE 161. DENMARK ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 162. DENMARK ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 163. EGYPT ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 164. EGYPT ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 165. EGYPT ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
  • TABLE 166. EGYPT ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
  • TABLE 167. EGYPT ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 168. EGYPT ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 169. FINLAND ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 170. FINLAND ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 171. FINLAND ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
  • TABLE 172. FINLAND ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
  • TABLE 173. FINLAND ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 174. FINLAND ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 175. FRANCE ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 176. FRANCE ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 177. FRANCE ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
  • TABLE 178. FRANCE ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
  • TABLE 179. FRANCE ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 180. FRANCE ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 181. GERMANY ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 182. GERMANY ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 183. GERMANY ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
  • TABLE 184. GERMANY ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
  • TABLE 185. GERMANY ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 186. GERMANY ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 187. ISRAEL ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 188. ISRAEL ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 189. ISRAEL ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
  • TABLE 190. ISRAEL ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
  • TABLE 191. ISRAEL ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 192. ISRAEL ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 193. ITALY ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 194. ITALY ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 195. ITALY ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
  • TABLE 196. ITALY ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
  • TABLE 197. ITALY ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 198. ITALY ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 199. NETHERLANDS ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 200. NETHERLANDS ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 201. NETHERLANDS ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
  • TABLE 202. NETHERLANDS ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
  • TABLE 203. NETHERLANDS ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 204. NETHERLANDS ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 205. NIGERIA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 206. NIGERIA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 207. NIGERIA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
  • TABLE 208. NIGERIA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
  • TABLE 209. NIGERIA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 210. NIGERIA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 211. NORWAY ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 212. NORWAY ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 213. NORWAY ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
  • TABLE 214. NORWAY ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
  • TABLE 215. NORWAY ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 216. NORWAY ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 217. POLAND ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 218. POLAND ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 219. POLAND ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
  • TABLE 220. POLAND ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
  • TABLE 221. POLAND ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 222. POLAND ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 223. QATAR ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 224. QATAR ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 225. QATAR ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
  • TABLE 226. QATAR ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
  • TABLE 227. QATAR ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 228. QATAR ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 229. RUSSIA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 230. RUSSIA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 231. RUSSIA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
  • TABLE 232. RUSSIA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
  • TABLE 233. RUSSIA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 234. RUSSIA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 235. SAUDI ARABIA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 236. SAUDI ARABIA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 237. SAUDI ARABIA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
  • TABLE 238. SAUDI ARABIA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
  • TABLE 239. SAUDI ARABIA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 240. SAUDI ARABIA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 241. SOUTH AFRICA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 242. SOUTH AFRICA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 243. SOUTH AFRICA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
  • TABLE 244. SOUTH AFRICA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
  • TABLE 245. SOUTH AFRICA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 246. SOUTH AFRICA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 247. SPAIN ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 248. SPAIN ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 249. SPAIN ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
  • TABLE 250. SPAIN ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
  • TABLE 251. SPAIN ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 252. SPAIN ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 253. SWEDEN ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 254. SWEDEN ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 255. SWEDEN ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
  • TABLE 256. SWEDEN ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
  • TABLE 257. SWEDEN ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 258. SWEDEN ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 259. SWITZERLAND ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 260. SWITZERLAND ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 261. SWITZERLAND ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
  • TABLE 262. SWITZERLAND ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
  • TABLE 263. SWITZERLAND ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 264. SWITZERLAND ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 265. TURKEY ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 266. TURKEY ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 267. TURKEY ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
  • TABLE 268. TURKEY ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
  • TABLE 269. TURKEY ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 270. TURKEY ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 271. UNITED ARAB EMIRATES ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 272. UNITED ARAB EMIRATES ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 273. UNITED ARAB EMIRATES ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
  • TABLE 274. UNITED ARAB EMIRATES ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
  • TABLE 275. UNITED ARAB EMIRATES ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 276. UNITED ARAB EMIRATES ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 277. UNITED KINGDOM ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 278. UNITED KINGDOM ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 279. UNITED KINGDOM ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
  • TABLE 280. UNITED KINGDOM ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
  • TABLE 281. UNITED KINGDOM ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 282. UNITED KINGDOM ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 283. ANTIBODY FRAGMENTS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 284. ANTIBODY FRAGMENTS MARKET, FPNV POSITIONING MATRIX, 2023